Ashwani Verma
Stock Analyst at UBS
(4.52)
# 1,012
Out of 4,468 analysts
209
Total ratings
61.5%
Success rate
14.8%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Rated: Hold | $40 → $52 | $55.85 | -6.89% | 9 | Jul 2, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $307 | $243.47 | +26.09% | 15 | Jul 1, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $161 → $208 | $174.26 | +19.36% | 18 | Jun 30, 2026 | |
| CYTK Cytokinetics | Upgraded: Buy | $69 → $115 | $86.49 | +32.96% | 13 | Jun 29, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $42 | $34.64 | +21.25% | 28 | Jun 26, 2026 | |
| INCY Incyte | Maintained: Hold | $103 → $113 | $116.86 | -3.30% | 12 | Jun 25, 2026 | |
| AMRX Amneal Pharmaceuticals | Reiterated: Buy | n/a | $17.15 | - | 2 | Jun 11, 2026 | |
| LEGN Legend Biotech | Rated: Buy | $31 → $49 | $29.91 | +63.82% | 8 | Jun 4, 2026 | |
| INSM Insmed | Reiterated: Buy | $166 | $111.60 | +48.75% | 7 | Jun 3, 2026 | |
| BHVN Biohaven | Reiterated: Hold | $11 | $15.96 | -31.08% | 6 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $37.09 | +29.41% | 1 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $95 → $72 | $90.21 | -20.19% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $48 | $54.58 | -12.06% | 7 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 → $57 | $57.77 | -1.33% | 11 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $259 | $244.31 | +6.01% | 12 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $6 | $3.61 | +66.20% | 3 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $645 → $705 | $555.91 | +26.82% | 19 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $20 | $16.70 | +19.76% | 5 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $40 | $25.97 | +54.02% | 10 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,080 | $1,213.91 | -11.03% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $220 | $261.07 | -15.73% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $43 | $37.26 | +15.41% | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 | $38.79 | -53.60% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.05 → $1.1 | $1.45 | -24.14% | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $119 → $130 | $216.12 | -39.85% | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $3.84 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.7713 | n/a | 1 | Oct 11, 2022 |
Exelixis
Jul 2, 2026
Rated: Hold
Price Target: $40 → $52
Current: $55.85
Upside: -6.89%
Jazz Pharmaceuticals
Jul 1, 2026
Maintained: Buy
Price Target: $307
Current: $243.47
Upside: +26.09%
Neurocrine Biosciences
Jun 30, 2026
Maintained: Buy
Price Target: $161 → $208
Current: $174.26
Upside: +19.36%
Cytokinetics
Jun 29, 2026
Upgraded: Buy
Price Target: $69 → $115
Current: $86.49
Upside: +32.96%
Teva Pharmaceutical Industries
Jun 26, 2026
Maintained: Buy
Price Target: $42
Current: $34.64
Upside: +21.25%
Incyte
Jun 25, 2026
Maintained: Hold
Price Target: $103 → $113
Current: $116.86
Upside: -3.30%
Amneal Pharmaceuticals
Jun 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $17.15
Upside: -
Legend Biotech
Jun 4, 2026
Rated: Buy
Price Target: $31 → $49
Current: $29.91
Upside: +63.82%
Insmed
Jun 3, 2026
Reiterated: Buy
Price Target: $166
Current: $111.60
Upside: +48.75%
Biohaven
May 28, 2026
Reiterated: Hold
Price Target: $11
Current: $15.96
Upside: -31.08%
May 27, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $37.09
Upside: +29.41%
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $90.21
Upside: -20.19%
May 6, 2026
Maintained: Buy
Price Target: $42 → $48
Current: $54.58
Upside: -12.06%
Apr 20, 2026
Maintained: Buy
Price Target: $49 → $57
Current: $57.77
Upside: -1.33%
Apr 10, 2026
Rated: Buy
Price Target: $251 → $259
Current: $244.31
Upside: +6.01%
Mar 24, 2026
Rated: Buy
Price Target: $10 → $6
Current: $3.61
Upside: +66.20%
Mar 5, 2026
Rated: Buy
Price Target: $645 → $705
Current: $555.91
Upside: +26.82%
Feb 27, 2026
Maintained: Buy
Price Target: $18 → $20
Current: $16.70
Upside: +19.76%
Jan 5, 2026
Maintained: Buy
Price Target: $35 → $40
Current: $25.97
Upside: +54.02%
Nov 7, 2025
Maintained: Buy
Price Target: $1,080
Current: $1,213.91
Upside: -11.03%
Nov 7, 2025
Maintained: Hold
Price Target: $220
Current: $261.07
Upside: -15.73%
Oct 14, 2025
Maintained: Buy
Price Target: $50 → $43
Current: $37.26
Upside: +15.41%
Jul 29, 2025
Maintained: Hold
Price Target: $18
Current: $38.79
Upside: -53.60%
Jul 21, 2025
Maintained: Hold
Price Target: $1.05 → $1.1
Current: $1.45
Upside: -24.14%
Jul 14, 2025
Maintained: Hold
Price Target: $119 → $130
Current: $216.12
Upside: -39.85%
Jun 17, 2025
Maintained: Buy
Price Target: $5
Current: $3.84
Upside: n/a
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.7713
Upside: n/a